PPAR delta comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-04-18. Numbers and descriptions here follow the published literature rather than marketing material.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | GW501516, GW-501516, GW 501516, endurobol | Names vary in research and anti-doping documents. |
| Chemical class | Synthetic PPARδ agonist | Small-molecule nuclear receptor ligand. |
| CAS Registry Number | 317318-70-0 | Identifier commonly associated with GW501516. |
| Appearance | White to off-white powder | Typical for purified research material. |
| Solubility | Low in water; soluble in DMSO and ethanol | Organic solvents are common for laboratory stock solutions. |
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
Label-free quantification is a method in mass spectrometry that aims to determine the relative amount of proteins in two or more biological samples. Unlike other methods for protein quantification, label-free quantification does not use a stable isotope containing compound to chemically bind to and thus label the protein.
==== Exact analytical solutions to the SIR model ==== In 2014, Harko and coauthors derived an exact so-called analytical solution (involving an integral that can only be calculated numerically) to the SIR model. In the case without vital dynamics setup, for
=== Spoon test === The spoon test, developed in 1964 by Ernest Bors, relies on assessment of the smooth movement of the convex side of a spoon along the surface of the patient's skin. In patients with sudomotor dysfunction, the spoon will slide in a smooth and uninterrupted fashion. Conversely, the spoon's movement in normal controls will be frequently interrupted by the presence of sweat on the skin. The spoon test is inexpensive, easy to perform, but subjective and not quantitative.
Pan pizza, baked in a pan with a crispy edge; "Stuffed crust" pizza, with the outermost edge wrapped around a cylinder of mozzarella cheese; "Hand-tossed", more like traditional pizzeria crusts; "Thin 'N Crispy", a thin, crisp dough which was Pizza Hut's original style; Dippin' Strips pizza, a pizza cut into small strips that can be dipped into a number of sauces; The P'Zone, a pizza-calzone hybrid with a marinara dipping sauce that comes in plain, Supremo, Meaty, and pepperoni; The Bigfoot pizza, its largest product; The Priazzo, a pie like pizza stuffed with pizza ingredients. The "stuffed crust" pizza was introduced on March 26, 1995. By the end of the year, it had become one of their most popular lines.
== Further reading == Rodrigues FB, Ferreira JJ (March 2017). "Opicapone for the treatment of Parkinson's disease" (PDF). Expert Opin Pharmacother. 18 (4): 445–453. doi:10.1080/14656566.2017.1294683. PMID 28234566. S2CID 5251815. Scott LJ (September 2016). "Opicapone: A Review in Parkinson's Disease". Drugs. 76 (13): 1293–1300. doi:10.1007/s40265-016-0623-y. PMID 27498199. S2CID 5787752.
Sources: en.wikipedia.org
The Headcrabs have received generally positive reception, identified as a series mascot due to existing merchandise. Kotaku writer Levi Winslow regarded encountering Headcrabs in Half-Life as among the most frightening moments in video games; they felt that the name itself was rather frightening, but the sight of it lunging for the player's head disgusted them. They found it particularly disgusting that, once it latches onto a person, it begins to take over their motor functions. Rock Paper Shotgun writer Adam Smith regarded the Headcrabs as among his favorite video game monsters, stating that they have many of the traits of the best monsters, including being small, hiding in dark spaces, leaping at people's faces, and the ability to turn people into zombies. In particular, the weaponization of Headcrabs in Half-Life 2 struck Smith, feeling that it represented a "credible extension" of the Headcrabs' role from Half-Life. He found the Poison Headcrabs to be particularly frightening, stating that he could not talk about them without "lift[ing] my feet onto the chair" out of anxiety of being bitten by one. Describing the Headcrab as "shamelessly ripped off" from the Facehuggers from the Alien series, GamesRadar+ writer Alex Avard felt that it was one of the most terrifying aliens for a multitude of reasons, including its leap attack, what happens if it latches onto a person's head, and the Headcrabs found in Ravenholm.
== Clinical significance == The Wnt signaling pathway was first linked to bone development when a loss-of-function mutation in LRP5 was found to cause osteoporosis-pseudoglioma syndrome. Shortly thereafter, two studies reported that gain-of-function mutations in LRP5 caused high bone mass. Many bone density related diseases are caused by mutations in the LRP5 gene. There is controversy whether bone grows through Lrp5 through bone or the intestine. The majority of the current data supports the concept that bone mass is controlled by LRP5 through the osteocytes. Mice with the same Lrp5 gain-of-function mutations also have high bone mass. The high bone mass is maintained when the mutation only occurs in limbs or in cells of the osteoblastic lineage. Bone mechanotransduction occurs through Lrp5 and is suppressed if Lrp5 is removed in only osteocytes. There are promising osteoporosis clinical trials targeting sclerostin, an osteocyte-specific protein which inhibits Wnt signaling by binding to Lrp5. An alternative model that has been verified in mice and in humans is that Lrp5 controls bone formation by inhibiting expression of TPH1, the rate-limiting biosynthetic enzyme for serotonin, a molecule that regulates bone formation, in enterochromaffin cells of the duodenum and that excess plasma serotonin leads to inhibition in bone. Another study found that a different Tph1-inhibitor decreased serotonin levels in the blood and intestine, but did not affect bone mass or markers of bone formation.
Ubayd Allah ibn Ziyad (Arabic: عُبَيْدِ اللَّهِ بْنِ زِيَادٍ, romanized: ʿUbayd Allāh ibn Ziyād) was the Umayyad governor of Basra, Kufa and Khurasan during the reigns of caliphs Mu'awiya I (r. 661–680) and Yazid I (r. 680–683), and the leading general of the Umayyad army under caliphs Marwan I (r. 684–685) and Abd al-Malik (r. 685–705). He virtually inherited the governorships from his father Ziyad ibn Abihi after the latter's death in 673. During Ubayd Allah's governorship, he suppressed Kharijite and Alid revolts. In the ensuing Battle of Karbala in 680, Husayn ibn Ali and his small retinue were slain by Ubayd Allah's troops, shocking many in the Muslim community. Ubayd Allah is primarily remembered for his role in the killings of members of Ali ibn Abi Talib's family and he has become infamous in Muslim tradition. Ubayd Allah was ultimately evicted from Iraq by the Arab tribal nobility amid the revolt of Abd Allah ibn al-Zubayr. He made it to Syria where he persuaded Marwan I to seek the caliphate and helped galvanize support for the flailing Umayyads. Afterward, he fought at the Battle of Marj Rahit in 684 against pro-Zubayrid tribes and helped reconstitute the Umayyad army. With this army he struggled against rebel Qaysi tribes in the Jazira before advancing against the Alids and Zubayrids of Iraq. However, he was slain and his forces routed at the Battle of Khazir by Ibrahim ibn al-Ashtar, the commander of the pro-Alid Mukhtar al-Thaqafi of Kufa.
=== Recommended diet === For the subset of patients whose homocystinuria is caused by cystathionine beta-synthase deficiency (i.e. those that do not respond to B6 supplementation), low-protein food is recommended for this disorder, which requires food products low in particular types of amino acids (e.g., methionine) in addition to supplementation.
Sources: en.wikipedia.org
== Applications == BMP has been shown to remain stable, without breaking down, in high-heat pasteurization and sterilization conditions, making it possible for potential use for culinary purposes. Those advocating for the presence of BMP's flavor-enhancing umami taste report that its taste is similar to that of monosodium glutamate. Consequently, BMP possesses potential for large-scale commercialization in the food industry. However, the primary obstacle is the cost of mass production associated with the peptide. Currently, the main modes of production for specific flavor peptides such as BMP are chemical and enzymatic synthesis, both of which involve high production costs.
== Other animals == Degenerative disc disease can occur in other mammals besides humans. It is a common problem in several dog breeds, such as the Dachshund, and attempts to remove this disease from dog populations have led to several hybrid breeds, such as the Chiweenie.
=== Composition === Fresh kava root contains on average 80% water. Dried root contains approximately 43% starch, 20% dietary fiber, 15% kavalactones, 12% water, 3.2% sugars, 3.6% protein, and 3.2% minerals. In general, kavalactone content is greatest in the roots and decreases higher up the plant into the stems and leaves. Relative concentrations of 15%, 10%, and 5% have been observed in the root, stump, and basal stems, respectively. The relative content of kavalactones depends not only on plant segment but also on the kava plant variety, plant maturity, geographic location, and time of harvest. The kavalactones present are kavain, desmethoxyyangonin, and yangonin, which are higher in the roots than in the stems and leaves, with dihydrokavain, methysticin, and dihydromethysticin also present. The mature roots of the kava plant are harvested after a minimum of four years (at least five years, ideally) for peak kavalactone content. Most kava plants produce around 50 kg (110 lb) of root when they are harvested. Kava root is classified into two categories: crown root (or chips) and lateral root. Crown roots are the large-diameter pieces that look like 1.5 to 5 inches (38 to 127 mm)-diameter wooden poker chips. Most kava plants consist of approximately 80% crown root upon harvesting. Lateral roots are smaller-diameter roots that look more like a typical root. A mature kava plant is about 20% lateral roots. Kava lateral roots have the highest content of kavalactones in the kava plant. "Waka" grade kava is made of lateral roots only.
Sources: en.wikipedia.org
Cardarine is an investigational synthetic compound that acts as a PPARδ agonist. It is also known as GW501516 and has been studied mainly in preclinical research. It is not an approved medicine.
No. Cardarine is not a steroid hormone; it targets the nuclear receptor PPARδ. Its classification in anti-doping rules differs from anabolic steroids, though it remains prohibited in sport.
Early rodent studies reported tumor formation at multiple sites, which raised safety concerns. Sponsors stopped clinical development, and no approved human product exists.
Cardarine is a common name for GW501516, a synthetic PPARδ agonist. It is not a steroid or a selective androgen receptor modulator. It was developed and studied as a research compound for metabolic pathways.